Semaglutide Research for Sleep Apnea
An evidence-based overview of research examining Semaglutide in the context of sleep apnea. This page synthesizes findings from peer-reviewed literature.
Research Summary
While not specifically FDA-approved for sleep apnea, semaglutide's substantial weight loss effects may benefit obstructive sleep apnea (OSA), which is strongly associated with obesity. Weight loss is a primary treatment recommendation for OSA. Tirzepatide, a related GLP-1/GIP dual agonist, received FDA approval for moderate-to-severe OSA in obesity (December 2024), suggesting GLP-1-based therapies have potential in this indication. The weight loss achieved with semaglutide (15-21%) exceeds thresholds typically associated with sleep apnea improvement. Dedicated clinical trials of semaglutide for sleep apnea would be needed to establish direct efficacy in this indication.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Sleep Apnea
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Semaglutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.